Category 3 abuse-deterrent study of the abuse-deterrent, extended-release morphine product Egalet 001.
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2016
At a glance
- Drugs Morphine (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Egalet
- 22 Sep 2016 Results published in an Egalet media release.
- 22 Sep 2016 Results from this and intranasal abuse potential trial (see CTP 700258174) published in Pain Medicine, according to an Egalet Corporation media release.
- 25 Aug 2016 According to an Egalet media release, the data of from trial would be presented PAINWeek 2016.